Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Acumen Pharmaceuticals (ABOS)
NASDAQ:ABOS
Acumen Pharmaceuticals (ABOS) Stock Price & Analysis
145 Followers
ABOS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.81 - $11.31
Previous Close$3.74
Volume184.18K
Average Volume (3M)358.33K
Market Cap
$224.70M
Enterprise Value$12.22M
Total Cash (Recent Filing)$243.52M
Total Debt (Recent Filing)$31.05M
Price to Earnings (P/E)-3.5
Beta0.61
Next Earnings
May 13, 2024EPS Estimate
-$0.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.08
Shares Outstanding60,079,778
10 Day Avg. Volume189,894
30 Day Avg. Volume358,332
Standard Deviation0.30
R-Squared0.00020
Alpha0.00163
Financial Highlights & Ratios
Price to Book (P/B)0.84
Price to Sales (P/S)44939.67
Price to Cash Flow (P/CF)-6.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.44K
Enterprise Value/Gross Profit2.44K
Enterprise Value/Ebitda-0.30
Forecast
1Y Price Target
$12.80Price Target Upside242.25% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Acumen Pharmaceuticals News
PremiumStock Analysis & Ideas
These 2 ‘Strong Buy’ Penny Stocks Are Poised for Over 300% Gains, Say Analysts
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
ABOS FAQ
What was Acumen Pharmaceuticals’s price range in the past 12 months?
Acumen Pharmaceuticals lowest stock price was $1.81 and its highest was $11.31 in the past 12 months.
What is Acumen Pharmaceuticals’s market cap?
Currently, no data Available
When is Acumen Pharmaceuticals’s upcoming earnings report date?
Acumen Pharmaceuticals’s upcoming earnings report date is May 13, 2024 which is in 25 days.
How were Acumen Pharmaceuticals’s earnings last quarter?
Acumen Pharmaceuticals released its earnings results on Mar 26, 2024. The company reported -$0.28 earnings per share for the quarter, missing the consensus estimate of -$0.274 by -$0.006.
Is Acumen Pharmaceuticals overvalued?
According to Wall Street analysts Acumen Pharmaceuticals’s price is currently Undervalued.
Does Acumen Pharmaceuticals pay dividends?
Acumen Pharmaceuticals does not currently pay dividends.
What is Acumen Pharmaceuticals’s EPS estimate?
Acumen Pharmaceuticals’s EPS estimate is -$0.26.
How many shares outstanding does Acumen Pharmaceuticals have?
Acumen Pharmaceuticals has 60,079,777 shares outstanding.
What happened to Acumen Pharmaceuticals’s price movement after its last earnings report?
Acumen Pharmaceuticals reported an EPS of -$0.28 in its last earnings report, missing expectations of -$0.274. Following the earnings report the stock price went down -11.765%.
Which hedge fund is a major shareholder of Acumen Pharmaceuticals?
Among the largest hedge funds holding Acumen Pharmaceuticals’s share is RA Capital Management. It holds Acumen Pharmaceuticals’s shares valued at 57M.
---
Acumen Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$12.80 (242.25% Upside)
$12.80 (242.25% Upside)
Blogger Sentiment
Bullish
ABOS Sentiment 100%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Negative
Last 7 Days ▼ 0.8%
Last 30 Days ▼ 0.1%
Last 30 Days ▼ 0.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-2.85%
12-Months-Change
Fundamentals
Return on Equity
-22.98%
Trailing 12-Months
Asset Growth
57.75%
Trailing 12-Months
Company Description
Acumen Pharmaceuticals
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what we believe to be a key underlying cause of Alzheimer's disease. The company's lead drug candidate, ACU193, is a subclass monoclonal antibody which selectively targets amyloid-beta oligomers.
---
ABOS Earnings Call
Q4 2024
0:00 / 0:00
---
ABOS Stock 12 Months Forecast
Average Price Target
$12.80
▲(242.25% Upside)
Technical Analysis
AbCellera Biologics
―
Arbutus Biopharma
―
Arrowhead Pharmaceuticals
―
American Bio Medica
―
Best Analysts Covering ABOS
1 Year
1 Year Success Rate
4/10 ratings generated profit
1 Year Average Return
-17.26%
reiterated a buy rating 23 days ago
Copying Andrew Fein's trades and holding each position for 1 Year would result in 40.00% of your transactions generating a profit, with an average return of -17.26% per trade.
---